Dr. Chan specializes in the surgical and medical treatment of ovarian and other
pelvic cancers at CPMC. He is board certified in gynecologic oncology, and obstetrics
and gynecology. He is investigating new treatments for gynecologic cancers,
including targeted biologic therapies, and exploring the role of tumor-initiating
cells in ovarian cancer. A clinician and surgeon, Dr. Chan is a principal investigator
of studies assessing the treatment and health outcomes of ovarian and uterine cancer
patients.
California Pacific Medical Center Research Institute
1501 Trousdale Drive
Burlingame, CA, 94010
(415) 751-1847
ChanJK@Sutterhealth.org
Primary Research Interests
- Biliary Cancer
- Brain Cancer
- Breast Cancer
- Cancer
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastrointestinal Cancer
- Head and Neck Cancer
- Hemotologic Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma
- Molecular/Rare Tumor
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rare Cancers
- Renal Cancer
- Sarcoma
- Skin Cancer
- Solid Tumors
- Urinary Tract Cancer
Related Clinical Trials
Locally Advanced or Metastatic (Roche YO40482)
Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab
to Patients With Advanced Platinum-sensitive Ovarian Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Locally Advanced or Metastatic (Syros SY 1365-101)
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced
Solid Tumors
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Targeted Therapies (ASCO TAPUR)
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Investigators: Ari Baron M.D., Caroline Behler MD, John Chung-Kai Chan M.D., Stacy D. D'Andre MD, Lejla Delic MD, Milana Dolezal MD, Stephanie Jeske MD, Gauri Kelekar MD, Kevin Kim MD, Bertrand Tuan MD, Wei Wang MD
Status: Active, Recruiting